Cancer Drugs Market by Type (Bladder Cancer, Blood Cancer, Breast Cancer), Application (Chemotherapy, Hormone Therapy, Immunotherapy) - Global Forecast 2024-2030

Cancer Drugs Market by Type (Bladder Cancer, Blood Cancer, Breast Cancer), Application (Chemotherapy, Hormone Therapy, Immunotherapy) - Global Forecast 2024-2030


The Cancer Drugs Market size was estimated at USD 80.36 billion in 2023 and expected to reach USD 88.48 billion in 2024, at a CAGR 10.19% to reach USD 158.59 billion by 2030.

Global Cancer Drugs Market

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cancer Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cancer Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences, Inc., GSK PLC, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage



This research report categorizes the Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Bladder Cancer
Blood Cancer
Breast Cancer
Gastrointestinal Cancer
Liver Cancer
Lung and Bronchus Cancer
Skin Cancer
Application
Chemotherapy
Hormone Therapy
Immunotherapy
Targeted Therapy
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Cancer Drugs Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cancer Drugs Market?
3. What are the technology trends and regulatory frameworks in the Cancer Drugs Market?
4. What is the market share of the leading vendors in the Cancer Drugs Market?
5. Which modes and strategic moves are suitable for entering the Cancer Drugs Market?

Note: PDF & Excel + Online Access - 1 Year


1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cancer Drugs Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of cancer across the globe and surge in global geriatric population
5.1.1.2. Increase in government expenditures on healthcare
5.1.1.3. Elevated development of biosimilar in oncology arena
5.1.2. Restraints
5.1.2.1. High cost and lack of availability of the drug
5.1.3. Opportunities
5.1.3.1. Increase in number of pipeline drugs
5.1.3.2. Growing R&D for development of effient cancer drugs
5.1.4. Challenges
5.1.4.1. Adverse effects associated with the use of cancer drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cancer Drugs Market, by Type
6.1. Introduction
6.2. Bladder Cancer
6.3. Blood Cancer
6.4. Breast Cancer
6.5. Gastrointestinal Cancer
6.6. Liver Cancer
6.7. Lung and Bronchus Cancer
6.8. Skin Cancer
7. Cancer Drugs Market, by Application
7.1. Introduction
7.2. Chemotherapy
7.3. Hormone Therapy
7.4. Immunotherapy
7.5. Targeted Therapy
8. Americas Cancer Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Cancer Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Cancer Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. AbbVie Inc.
12.1.2. Amgen Inc.
12.1.3. Astellas Pharma Inc.
12.1.4. AstraZeneca PLC
12.1.5. Bayer AG
12.1.6. Bristol-Myers Squibb Company
12.1.7. Eli Lilly and Company
12.1.8. Gilead Sciences, Inc.
12.1.9. GSK PLC
12.1.10. Johnson & Johnson
12.1.11. Merck & Co., Inc.
12.1.12. Novartis AG
12.1.13. Pfizer Inc.
12.1.14. Sanofi SA
12.1.15. Takeda Pharmaceutical Company Limited
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
FIGURE 1. CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. CANCER DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CANCER DRUGS MARKET DYNAMICS
FIGURE 7. CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CANCER DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 10. CANCER DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings